221 related articles for article (PubMed ID: 36329160)
1. Impact of IL-15 and latency reversing agent combinations in the reactivation and NK cell-mediated suppression of the HIV reservoir.
Covino DA; Desimio MG; Doria M
Sci Rep; 2022 Nov; 12(1):18567. PubMed ID: 36329160
[TBL] [Abstract][Full Text] [Related]
2. Combinations of Histone Deacetylase Inhibitors with Distinct Latency Reversing Agents Variably Affect HIV Reactivation and Susceptibility to NK Cell-Mediated Killing of T Cells That Exit Viral Latency.
Covino DA; Desimio MG; Doria M
Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34206330
[TBL] [Abstract][Full Text] [Related]
3. Innate Immune Activity Correlates with CD4 T Cell-Associated HIV-1 DNA Decline during Latency-Reversing Treatment with Panobinostat.
Olesen R; Vigano S; Rasmussen TA; Søgaard OS; Ouyang Z; Buzon M; Bashirova A; Carrington M; Palmer S; Brinkmann CR; Yu XG; Østergaard L; Tolstrup M; Lichterfeld M
J Virol; 2015 Oct; 89(20):10176-89. PubMed ID: 26223643
[TBL] [Abstract][Full Text] [Related]
4. In Vitro Reactivation of Replication-Competent and Infectious HIV-1 by Histone Deacetylase Inhibitors.
Banga R; Procopio FA; Cavassini M; Perreau M
J Virol; 2016 Feb; 90(4):1858-71. PubMed ID: 26656693
[TBL] [Abstract][Full Text] [Related]
5. Short Communication: The Broad-Spectrum Histone Deacetylase Inhibitors Vorinostat and Panobinostat Activate Latent HIV in CD4(+) T Cells In Part Through Phosphorylation of the T-Loop of the CDK9 Subunit of P-TEFb.
Jamaluddin MS; Hu PW; Jan Y; Siwak EB; Rice AP
AIDS Res Hum Retroviruses; 2016 Feb; 32(2):169-73. PubMed ID: 26727990
[TBL] [Abstract][Full Text] [Related]
6. In vivo analysis of the effect of panobinostat on cell-associated HIV RNA and DNA levels and latent HIV infection.
Tsai P; Wu G; Baker CE; Thayer WO; Spagnuolo RA; Sanchez R; Barrett S; Howell B; Margolis D; Hazuda DJ; Archin NM; Garcia JV
Retrovirology; 2016 May; 13(1):36. PubMed ID: 27206407
[TBL] [Abstract][Full Text] [Related]
7. Interleukin-15-Stimulated Natural Killer Cells Clear HIV-1-Infected Cells following Latency Reversal
Garrido C; Abad-Fernandez M; Tuyishime M; Pollara JJ; Ferrari G; Soriano-Sarabia N; Margolis DM
J Virol; 2018 Jun; 92(12):. PubMed ID: 29593039
[TBL] [Abstract][Full Text] [Related]
8. Class 1-Selective Histone Deacetylase (HDAC) Inhibitors Enhance HIV Latency Reversal while Preserving the Activity of HDAC Isoforms Necessary for Maximal HIV Gene Expression.
Zaikos TD; Painter MM; Sebastian Kettinger NT; Terry VH; Collins KL
J Virol; 2018 Mar; 92(6):. PubMed ID: 29298886
[TBL] [Abstract][Full Text] [Related]
9. Identification of Novel HIV-1 Latency-Reversing Agents from a Library of Marine Natural Products.
Richard K; Williams DE; de Silva ED; Brockman MA; Brumme ZL; Andersen RJ; Tietjen I
Viruses; 2018 Jun; 10(7):. PubMed ID: 29954099
[TBL] [Abstract][Full Text] [Related]
10. The HIV Latency Reversal Agent HODHBt Enhances NK Cell Effector and Memory-Like Functions by Increasing Interleukin-15-Mediated STAT Activation.
Macedo AB; Levinger C; Nguyen BN; Richard J; Gupta M; Cruz CRY; Finzi A; Chiappinelli KB; Crandall KA; Bosque A
J Virol; 2022 Aug; 96(15):e0037222. PubMed ID: 35867565
[TBL] [Abstract][Full Text] [Related]
11. TLR1/2 Agonist Enhances Reversal of HIV-1 Latency and Promotes NK Cell-Induced Suppression of HIV-1-Infected Autologous CD4
Duan S; Xu X; Wang J; Huang L; Peng J; Yu T; Zhou Y; Cheng K; Liu S
J Virol; 2021 Aug; 95(17):e0081621. PubMed ID: 34133900
[TBL] [Abstract][Full Text] [Related]
12. Entinostat is a histone deacetylase inhibitor selective for class 1 histone deacetylases and activates HIV production from latently infected primary T cells.
Wightman F; Lu HK; Solomon AE; Saleh S; Harman AN; Cunningham AL; Gray L; Churchill M; Cameron PU; Dear AE; Lewin SR
AIDS; 2013 Nov; 27(18):2853-62. PubMed ID: 24189584
[TBL] [Abstract][Full Text] [Related]
13. Histone deacetylase inhibitors induce complex host responses that contribute to differential potencies of these compounds in HIV reactivation.
Beliakova-Bethell N; Mukim A; White CH; Deshmukh S; Abewe H; Richman DD; Spina CA
J Biol Chem; 2019 Apr; 294(14):5576-5589. PubMed ID: 30745362
[TBL] [Abstract][Full Text] [Related]
14. 4-Deoxyphorbol inhibits HIV-1 infection in synergism with antiretroviral drugs and reactivates viral reservoirs through PKC/MEK activation synergizing with vorinostat.
De la Torre-Tarazona HE; Jiménez R; Bueno P; Camarero S; Román L; Fernández-García JL; Beltrán M; Nothias LF; Cachet X; Paolini J; Litaudon M; Alcami J; Bedoya LM
Biochem Pharmacol; 2020 Jul; 177():113937. PubMed ID: 32224142
[TBL] [Abstract][Full Text] [Related]
15. Genome-wide CRISPR screens identify combinations of candidate latency reversing agents for targeting the latent HIV-1 reservoir.
Dai W; Wu F; McMyn N; Song B; Walker-Sperling VE; Varriale J; Zhang H; Barouch DH; Siliciano JD; Li W; Siliciano RF
Sci Transl Med; 2022 Oct; 14(667):eabh3351. PubMed ID: 36260688
[TBL] [Abstract][Full Text] [Related]
16. Sequential treatment with 5-aza-2'-deoxycytidine and deacetylase inhibitors reactivates HIV-1.
Bouchat S; Delacourt N; Kula A; Darcis G; Van Driessche B; Corazza F; Gatot JS; Melard A; Vanhulle C; Kabeya K; Pardons M; Avettand-Fenoel V; Clumeck N; De Wit S; Rohr O; Rouzioux C; Van Lint C
EMBO Mol Med; 2016 Feb; 8(2):117-38. PubMed ID: 26681773
[TBL] [Abstract][Full Text] [Related]
17. Synergistic activation of HIV-1 expression by deacetylase inhibitors and prostratin: implications for treatment of latent infection.
Reuse S; Calao M; Kabeya K; Guiguen A; Gatot JS; Quivy V; Vanhulle C; Lamine A; Vaira D; Demonte D; Martinelli V; Veithen E; Cherrier T; Avettand V; Poutrel S; Piette J; de Launoit Y; Moutschen M; Burny A; Rouzioux C; De Wit S; Herbein G; Rohr O; Collette Y; Lambotte O; Clumeck N; Van Lint C
PLoS One; 2009 Jun; 4(6):e6093. PubMed ID: 19564922
[TBL] [Abstract][Full Text] [Related]
18. Ex Vivo Bioactivity and HIV-1 Latency Reversal by Ingenol Dibenzoate and Panobinostat in Resting CD4(+) T Cells from Aviremic Patients.
Spivak AM; Bosque A; Balch AH; Smyth D; Martins L; Planelles V
Antimicrob Agents Chemother; 2015 Oct; 59(10):5984-91. PubMed ID: 26169416
[TBL] [Abstract][Full Text] [Related]
19. HDAC inhibitors Panobinostat and Romidepsin enhance
Schnell AP; Kohrt S; Aristodemou A; Taylor GP; Bangham CRM; Thoma-Kress AK
Front Immunol; 2022; 13():978800. PubMed ID: 36052071
[TBL] [Abstract][Full Text] [Related]
20. The thioacetate-ω(γ-lactam carboxamide) HDAC inhibitor ST7612AA1 as HIV-1 latency reactivation agent.
Badia R; Grau J; Riveira-Muñoz E; Ballana E; Giannini G; Esté JA
Antiviral Res; 2015 Nov; 123():62-9. PubMed ID: 26348004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
